Cost-effectiveness model of Palivizumab in The Netherlands

被引：0
|
作者：
Nuijten, MJ
Lebmeier, M
Daalderop, P
Wittenberg, W
机构：
[1] Erasmus Univ, Jisp, AL, Netherlands
[2] Univ Sheffield, Sheffield, S Yorkshire, England
[3] Abbott BV, Hoofddorp, Netherlands
[4] Dept Hlth Econ & Outcomes Res, Ludwigshafen, Germany
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67298-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A52 / A52
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF PALIVIZUMAB IN THE PROPHYLAXIS OF SEVERE BRONCHIOLITIS CAUSED BY RSV: RESULTS OF A DECISION MODEL WITH LOCAL DATA
    Garcia-Altes, A.
    Paladio, N.
    Pons, J.
    Tebe, C.
    VALUE IN HEALTH, 2008, 11 (06) : A432 - A433
  • [32] Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial
    Thurston, S. J.
    Heeg, B.
    de Charro, F.
    van Hout, B.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (03) : 641 - 651
  • [33] Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease
    ElHassan, Nahed O.
    Sorbero, Melony E. S.
    Hall, Caroline B.
    Stevens, Timothy P.
    Dick, Andrew W.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2006, 160 (10): : 1070 - 1076
  • [34] The Cost-Effectiveness of Palivizumab in the Prevention of Respiratory Syncytial Virus Bronchiolitis: A Systematic Review
    Blanken, Maarten
    Bont, Louis
    Rovers, Maroeska
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2011, 7 (03) : 203 - 212
  • [35] Methodological Concerns Regarding Cost-effectiveness Analysis of Palivizumab in Florida Medicaid reply
    Hampp, Christian
    Kauf, Teresa L.
    Saidi, Arwa S.
    Winterstein, Almut G.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2012, 166 (10): : 969 - 970
  • [36] Cost-effectiveness of Palivizumab in premature infants less than 32 weeks GA
    Gribar, S
    Alur, R
    Parimi, P
    PEDIATRIC RESEARCH, 2000, 47 (04) : 400A - 400A
  • [37] COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB WITH RISK FACTORS FOR RESPIRATORY SYNCYTIAL VIRUS PREVENTION
    Lee, M. Y.
    Lee, E. K.
    VALUE IN HEALTH, 2012, 15 (07) : A398 - A398
  • [38] COST-EFFECTIVENESS OF PALIVIZUMAB IN PREMATURE INFANTS AND CHILDREN WITH CHRONIC LUNG DISEASE IN MEXICO
    Major, I
    Pichardo-Pina, C. A.
    Sanchez-Casillas, J. L.
    Schmidt, R.
    Vo, P.
    VALUE IN HEALTH, 2015, 18 (07) : A834 - A834
  • [39] Cost-effectiveness estimates for antenatal HIV testing in the Netherlands
    Rozenbaum, M. H.
    Verweel, G.
    Folkerts, D. K. F.
    Dronkers, F.
    van den Hoek, J. A. R.
    Hartwig, N. G.
    de Groot, R.
    Postma, M. J.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2008, 19 (10) : 668 - 675
  • [40] Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
    Mangen, Marie-Josee J.
    Rozenbaum, Mark H.
    Huijts, Susanne M.
    van Werkhoven, Cornelis H.
    Postma, Douwe F.
    Atwood, Mark
    van Deursen, Anna M. M.
    van der Ende, Arie
    Grobbee, Diederick E.
    Sanders, Elisabeth A. M.
    Sato, Reiko
    Verheij, Theo J. M.
    Vissink, Conrad E.
    Bonten, Marc J. M.
    de Wit, G. Ardine
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (05) : 1407 - 1416
12345